Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 8 от 154

Набира участници

Nectero EAST System Retreatment Study

AAA - Abdominal Aortic Aneurysm Aorta Aneurysm Dilation Aorta

This is an exploratory pilot study to evaluate the safety and clinical utility of retreatment with an investigational combination product called the Nectero EAST System to treat Abdominal Aortic Aneurysms or AAA.

Начало: 01.03.2026 Край: 01.02.2029 Възраст: 21–85 г. Лечение

Australia, New Zealand Nectero Medical, Inc. NCT07505082

Набира участници

Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

NSCLC (Non-small Cell Lung Cancer)

This study aims to evaluate the safety of the CAROL device for treating lung tumors in patients diagnosed with non-small cell lung cancer (NSCLC) with tumor size ≤ 2 cm (cT1b). The primary objective is to assess safety by monitoring and grading adverse events using the CTCAE v5.0 criteria at one month following the procedure.

Начало: 01.03.2026 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia Tau Medical Australia Pty Ltd NCT07122258

Набира участници

Kidney Protective Jacket

Kidney Transplant

This is a safety study designed to investigate the safety of utilizing the Kidney Protective Jacket (KPJ)™ during kidney transplantation. In general, we aim to use the device in all possible recipients, aiming to demonstrate its safety in the variable circumstances that may arise during kidney transplantation, e.g. single or multiple renal vessels, different-sized kidneys, and variable recipient size and weight.

Начало: 01.03.2026 Край: 31.12.2026 Възраст: от 18 г. Друго

Australia iiShield NCT07348458

Набира участници

Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery

Acute Kidney Injury

This project aims to conduct an international, prospective, multicentre, observational study to determine the incidence of Postoperative Acute Kidney Injury (PO-AKI) in hospitalized children after noncardiac surgery. Urinary biomarkers are intended to be evaluated as predictors of PO-AKI in the same subjects. The study employs modern standardized classifications for AKI to comprehensively address the issue of PO-AKI in children. Describing the incidence and identifying risk factors for PO-AKI will play a crucial role in developing preventive strategies aimed at reducing associated mortality and morbidity. Furthermore, investigating the relationship between urinary biomarkers of renal injury and PO-AKI will provide valuable insights into assessing postoperative renal function in paediatric patients, especially when repeated blood sampling is not feasible.

Начало: 01.03.2026 Край: 31.12.2028 Възраст: до 16 г.

Australia, Brazil, France +3 Uppsala University NCT07351149

Набира участници Фаза 1

A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers

Healthy Male Participants

This phase I study is to compare the pharmacokinetics (PK), immunogenicity, safety, and tolerability of Bmab3000 (test) and Herceptin Hylecta (reference) after a single subcutaneous (s.c.) dose in healthy male volunteers.

Начало: 28.02.2026 Край: 30.06.2026 Възраст: 18–65 г. Лечение

New Zealand Biocon Biologics UK PLC NCT07299955

Набира участници

INOPASE - Performance and Safety Study of a Personalised SNM System

Overactive Bladder (OAB)

The goal of this clinical trial is to learn whether a new sacral neuromodulation (SNM) system (INO-SNM-01) can safely and effectively sense bladder nerve activity and provide stimulation to help manage symptoms of refractory overactive bladder in adult women aged 18-70 who have not responded to standard treatments. The main questions it aims to answer are: * Is there a clear relationship between bladder nerve activity and patient-reported urgency sensations? * Can targeted stimulation based on bladder nerve activity reduce overactive bladder symptoms? * Is the INO-SNM-01 System safe to use? Researchers will not use a comparison group in this study. Instead, all participants will receive the investigational device to see if it works as intended. Participants will undergo surgery to have a temporary trial lead implanted near the sacral nerve and spend up to 2 days in hospital for monitoring and testing to assess the device sensing and stimulation capabilities. Up to 10 participants will take part in this first-in-human feasibility study at a single site in Australia.

Начало: 27.02.2026 Край: 31.12.2026 Възраст: 18–70 г. Устройства

Australia INOPASE Pty Ltd NCT07193407

Набира участници

Physical Activity and Exercise During Early Treatment Phases for Childhood Acute Lymphoblastic Leukaemia to Protect Against Muscle Loss and Improve Frailty Outcomes

Sarcopenia Acute Lymphoblastic Leukemia

This is a small trial testing out a new approach before doing a bigger study. Researchers are observing a group of children/adolescents (ages 5-17) with acute lymphoblastic leukemia (ALL) and testing a physical activity and exercise program on a group of them who after 5 weeks of treatment show signs of weakness or frailty. Kids who are NOT losing muscle aren't part of the exercise trial - they're just monitored over time to see how they do. The goal: To see if an exercise program helps kids who are getting weaker from acute lymphoblastic leukemia treatment build back/maintain their strength, compared to kids who don't do the extra intervention. The study will also look at if this way of measuring muscle weakness works well for kids with cancer.

Начало: 24.02.2026 Край: 01.10.2028 Възраст: 5–17 г. Превенция

Australia Murdoch Childrens Research Institute NCT07325305

Набира участници

Prevention of Stretch Marks in Expectant Mothers

Pregnant Women Stretch Mark

PRIME Mothers is a national observational trial designed to evaluate patient outcomes with Stratamark® for the prevention of stretch marks during pregnancy and the postpartum period. The study is designed to fit seamlessly into routine clinical practice, with digital follow-up and home resupply, minimising clinic involvement.

Начало: 24.02.2026 Край: 01.02.2027 Възраст: от 18 г.

Australia Stratpharma AG NCT07467837

Набира участници Фаза 3

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Obesity

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Начало: 24.02.2026 Край: 21.08.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +5 Novo Nordisk A/S NCT07339423

Набира участници

False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study

Aortic Dissection

To determine the safety and feasibility of the investigational product to reduce aortic dissection false lumen perfusion.

Начало: 24.02.2026 Край: 15.02.2029 Възраст: от 18 г. Лечение

New Zealand Shape Memory Medical, Inc. NCT06550986

Набира участници Фаза 3

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Relapsed Refractory Multiple Myeloma

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.

Начало: 23.02.2026 Край: 29.07.2030 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +11 AstraZeneca NCT07391657

Набира участници Фаза 1

A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B

Chronic Hepatitis B Virus Infection

This study will examine the safety and tolerability of single and multiple doses of IB-001, and will be conducted in two parts: Part A: SAD study in approximately 60 Healthy Volunteers (HV). Part B: MAD study in approximately 30 adult participants living with Chronic Hepatitis B (CHB).

Начало: 20.02.2026 Край: 01.07.2027 Възраст: 18–70 г. Лечение

New Zealand IntegerBio NCT07389044

Набира участници Фаза 1/2

UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies

Peanut-Induced Anaphylaxis Peanut Allergy

This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.

Начало: 18.02.2026 Край: 01.11.2027 Възраст: 18–55 г. Лечение

Australia, New Zealand Ukko Inc NCT07349212

Набира участници Фаза 3

A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

Acute Ischemic Stroke

This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Participants need to have imaging that shows there is brain tissue that can still be saved. They also should not be planned to receive a procedure to remove the blood clot. The purpose of this study is to find out whether a medicine called tenecteplase helps people recover from an acute stroke. Tenecteplase is already used to treat people within 4.5 hours after they had a stroke. This study tests if tenecteplase also helps if it is given more than 4.5 hours after the stroke. Participants are put into 2 groups randomly, which means by chance. One group gets tenecteplase as a single injection into a vein. The other group receives standard medical practice. Participants have an equal chance of receiving tenecteplase or the standard treatment. Participants are in the study for about 3 months. In the beginning, participants stay in the hospital for about 1 week. During the study, participants have 7 clinical examinations or visits. The last 2 of these visits will likely be done from home, allowing participants to complete certain assessments remotely. Doctors regularly test participants' recovery using a scale that measures the level of disability or dependence in daily activities. The results are compared between the 2 groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.

Начало: 17.02.2026 Край: 02.10.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Bulgaria +12 Boehringer Ingelheim NCT07361302

Набира участници Фаза 3

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis

This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS. Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine. Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS. Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Начало: 16.02.2026 Край: 18.12.2029 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +29 Boehringer Ingelheim NCT07220083

Набира участници Фаза 1

Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult Smokers

Healthy Healthy Smoker

This is a 3-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled RB042.

Начало: 16.02.2026 Край: 01.02.2027 Възраст: 18–55 г. Лечение

Australia RAGE Bio NCT07285122

Набира участници Ранна Фаза 1

A Study of APL-10456-Vaccine

Rhinovirus

AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of APL-10456-Vaccine, a Rhinovirus (RV) Vaccine, when compared with a placebo in Younger and Older Healthy Volunteers

Начало: 16.02.2026 Край: 21.10.2027 Възраст: от 18 г. Превенция

Australia Apollo Therapeutics Ltd NCT07399132

Набира участници Фаза 1

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

Advanced Malignancy Advanced Solid Cancers Metastatic Solid Tumors

The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors. ADCX-020 is an investigational anticancer therapy called antibody drug conjugate. This study is set up in multiple parts. In the first part of the study, participants receive increasing doses of ADCX-020. Then 2 or more doses will be assessed to identify the optimal dose. This optimal dose is subsequently evaluated for effect on different cancer types.

Начало: 14.02.2026 Край: 30.11.2029 Възраст: от 18 г. Лечение

Australia Adcytherix SAS NCT07238075

Набира участници

Scaffold-guided Breast Implant Revision Surgery

Breast Implant Revision Breast Augmentation Complications

The objective of this clinical trial is to generate robust data that demonstrates clinical performance and safety of a polycaprolactone (PCL) breast scaffold combined with autologous fat grafting (AFG) in women who seek a revision surgery of a breast implant used for breast augmentation. The material (PCL) has been in clinical use for many decades and is absorbable. This study follows the successful completion of a 2-year evaluation of the safety and feasibility of this technique performed by the Royal Brisbane and Women's Hospital (ClinicalTrials.gov ID: NCT05437757). The main question it aims to answer is: "Is PCL Breast Scaffold with autologous fat graft a safe and effective method of soft tissue reconstruction following breast implant revision?". Participants will: * Undergo removal of their existing silicone breast implant (if not previously removed), * Receive implantation of a PCL Breast Scaffold combined with autologous fat grafting (AFG), and * Attend follow-up visits at 1 week, 3 months, 6 months, and annually for up to 5 years for clinical assessments and questionnaires.

Начало: 13.02.2026 Край: 01.01.2032 Възраст: от 18 г. Друго

Australia, Denmark BellaSeno Pty Ltd NCT07367698

Набира участници Фаза 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight Obesity

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

Начало: 10.02.2026 Край: 01.07.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +11 Eli Lilly and Company NCT07392190

1 … 6 7 8 9 10 … 154